Canadian patent boosts AAT treatment

Israel’s Kamada has been allowed a patent in Canada for the large-scale production of Alpha-1 Proteinase Inhibitor. The process is key to Kamada’s treatments for alpha-1 antitrypsin (AAT) deficient patients suffering from type-1 diabetes and pulmonary diseases, amongst others.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *